The ecto-enzyme CD38 is gaining momentum as a novel therapeutic target for patients with hematological malignancies, with several anti-CD38 monoclonal antibodies in clinical trials with promising ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results